topotecan has been researched along with dactinomycin in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gibbons, S; Kaatz, GW; Zloh, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Weller, M; Winter, S | 1 |
| Anderson, JR; Breneman, JC; Crist, WM; Donaldson, SS; Grier, HE; Link, MP; Maurer, HM; Paidas, CN; Pappo, AS; Qualman, SJ; Raney, RB; Smith, LM; Teot, LA; Wiener, ES | 1 |
| Anderson, JR; Barr, FG; Crist, WM; Donaldson, SS; Maurer, HM; Pappo, AS; Qualman, SJ; Raney, RB; Wiener, ES | 1 |
| Breitfeld, PP; Lyden, ER; Meyer, WH; Qualman, SJ; Walterhouse, DO; Wharam, MD | 1 |
| Alders, M; Cransberg, K; Loos, WJ; Lugtenberg, RT; van den Heuvel-Eibrink, MM; Wagner, A | 1 |
| Anderson, JR; Arndt, CA; Breneman, JC; Donaldson, SS; Hawkins, DS; Hayes-Jordan, AA; Meyer, WH; Paidas, CN; Parham, DM; Rodeberg, DA; Stoner, JA; Teot, LA; Wharam, MD | 1 |
| Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Anderson, JR; Arndt, CA; Donaldson, SS; Hawkins, DS; Lyden, ER; Morris, CD; Rodeberg, DA; Wolden, SL | 1 |
| Brabetz, S; Chan, JA; Herold-Mende, C; Kool, M; Korshunov, A; Mack, N; Milde, T; Pfister, SM; Schmidt, C; Schubert, NA; Schwalm, B; Selt, F; Witt, O | 1 |
2 review(s) available for topotecan and dactinomycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infant; Male; Melphalan; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Rhabdomyosarcoma; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Topotecan; Treatment Outcome; Vincristine | 2001 |
3 trial(s) available for topotecan and dactinomycin
| Article | Year |
|---|---|
Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Female; Humans; Male; Neoplasm Metastasis; Rhabdomyosarcoma; Survival Analysis; Topotecan; Vincristine | 2004 |
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Female; Humans; Infant; Kaplan-Meier Estimate; Male; Neoplasm Staging; Rhabdomyosarcoma; Topotecan; Vincristine | 2009 |
Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Disease Progression; Disease-Free Survival; Female; Humans; Infant; Lymph Nodes; Male; Meningeal Neoplasms; Radiotherapy Dosage; Retroperitoneal Neoplasms; Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal; Topotecan; Treatment Failure; Tumor Burden; Vincristine | 2015 |
9 other study(ies) available for topotecan and dactinomycin
| Article | Year |
|---|---|
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Cell Membrane; Drug Resistance, Microbial; Drug Resistance, Multiple; Ligands; Models, Molecular | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dactinomycin; Dose-Response Relationship, Drug; Drug Synergism; Fas Ligand Protein; fas Receptor; Glioma; Humans; Membrane Glycoproteins; Mice; Proto-Oncogene Proteins c-bcl-2; RNA; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Follow-Up Studies; Humans; Infant; Multivariate Analysis; Neoplasm Recurrence, Local; Prognosis; Rhabdomyosarcoma; Soft Tissue Neoplasms; Survival Rate; Topotecan; Treatment Failure; Vincristine | 2001 |
Topotecan distribution in an anephric infant with therapy-resistant bilateral Wilms tumor with a novel germline WT1 gene mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Dactinomycin; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Exons; Female; Frameshift Mutation; Genes, Wilms Tumor; Germ-Line Mutation; Humans; Infant; Kidney Neoplasms; Loss of Heterozygosity; Metabolic Clearance Rate; Nephrectomy; Peritoneal Dialysis; Polymorphism, Single Nucleotide; RNA Splice Sites; Sequence Analysis, DNA; Topotecan; Vincristine; Wilms Tumor | 2008 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine | 2011 |
Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Proliferation; Child, Preschool; Dactinomycin; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors, Primitive; Pteridines; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |